u/osman_ferrari

Research-use-only material is not approved for human use. In this catalogue that covers essentially everything, which is why the board discusses material and analytics rather than outcomes.

Fasting or postprandial?

Certain conditions affect A1c independently of glycaemia. If a result looks inconsistent with the sensor data, that is a question for whoever manages your care rather than for this board.

Ordered under a name that turned out to cover two different molecules. Nobody’s fault but mine for not asking.

the trials that looked at withdrawal are unambiguous about what follows

the second-level appeal is where things actually turn

seven days to ten to twelve is the sequence people here describe

Push back: that is not a plateau, that is maintenance. You have arrived and you are describing it as a failure.

The diabetes and obesity programmes are separate, with different populations and different primary endpoints. Reading a result across from one to the other is not a comparison.

Agreed that a few kilos of drift is ordinary. Weight is not a fixed number even for people who have never taken anything.

Push back: one sensor reading is not a data point worth acting on, especially in the first day of wear.

Disagreeing with this line: that endpoint is from the obesity programme and does not answer the question.

Appetite returning before the scale moves follows from the mechanism: the appetite effect is the proximal one and weight is the lagging integrated outcome.

Delayed gastric emptying is most pronounced early and attenuates with continued dosing, which is why the reflux usually fades at a stable dose.

appetite returns before the scale acknowledges anything

Careful. A four-week stall is inside normal variation and treating it as failure is how people escalate for no reason.

I would not compare your numbers to that population. Different baseline, different regimen, different trial.

Body weight varies by a couple of kilos over days in stable people through fluid, glycogen and gut content. A range is not a trend.

Cosigning.

This is the part I would underline for anyone skimming. Everything else in the thread is downstream of it.

monthly weigh-ins are enough at this stage

the fasting number is the one people fixate on and it moves last

britt_abubakar is right that the fasting number moves last. Knowing that in advance saves months of worry.

ask what the reference standard was

Net peptide content accounts for counterion, water and residual solvent. On some of these compounds the gap between purity and net content is substantial and entirely honest.

Yes. Written, always, even when they tell you a phone call is sufficient.

Not convinced. Interval stretching changes your exposure profile, not just the total, and the two are not equivalent.

Have you taken this to whoever manages your diabetes?

check the trial population before quoting a result at somebody

dose for glycaemic control is not the same conversation as dose for weight

Employer-sponsored plans may be regulated differently from individually purchased ones, which changes both the appeal route and which regulator hears a complaint.

formulary decisions are provincial, so the province is the first fact

Disagreeing with this line: that is an employer plan process and the provincial one differs.

Kept a log with every date, name of department and reference number. When they claimed no record of a call, I had the reference.

do not chase the last two kilos with a dose increase

Yes. Approval and coverage are separate, and this board conflates them in about half its threads.

Push back: handling advice from one compound does not transfer to another just because both are peptides.

Not convinced. That is a formulary exclusion rather than a prior authorisation denial, and the route to challenge it is different.

Disagree — that name refers to at least two different molecules depending on who is selling it. The thread needs to be specific.

the sequence is the product, everything else is packaging

Employer-sponsored plans may be regulated differently from individually purchased ones, which changes both the appeal route and which regulator hears a complaint.